Knocking down or pharmacologically inhibiting the RET kinase in various mouse and human neuroendocrine PCa models significantly diminished PCa tumor growth and cellular vitality (VanDeusen et al., 2020). The gene discussed is RET; the disease is posterior cortical atrophy.